Show simple item record

dc.contributor.authorRanson, Malcolm R
dc.date.accessioned2009-08-27T13:59:45Z
dc.date.available2009-08-27T13:59:45Z
dc.date.issued2003-10
dc.identifier.citationTechnology evaluation: ABX-EGF, Abgenix/Amgen. 2003, 5 (5):541-6 Curr. Opin. Mol. Ther.en
dc.identifier.issn1464-8431
dc.identifier.pmid14601524
dc.identifier.urihttp://hdl.handle.net/10541/78899
dc.description.abstractAbgenix and Amgen (formerly Immunex) are developing ABX-EGF, a human monoclonal antibody against the epidermal growth factor receptor, for potential use in the treatment of cancer. ABX-EGF is undergoing phase II trials in patients with renal, colorectal, prostate and non-small-cell lung cancers. By July 2002, phase III trials for these indications were planned to start in 2003.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAnimals
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntineoplastic Agents
dc.subject.meshClinical Trials, Phase I as Topic
dc.subject.meshClinical Trials, Phase II as Topic
dc.subject.meshHumans
dc.subject.meshMice
dc.subject.meshMice, Transgenic
dc.subject.meshNeoplasms
dc.subject.meshReceptor, Epidermal Growth Factor
dc.titleTechnology evaluation: ABX-EGF, Abgenix/Amgen.en
dc.typeArticleen
dc.contributor.departmentUniversity of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK. malcolm.ranson@man.ac.uken
dc.identifier.journalCurrent Opinion in Molecular Therapeuticsen
html.description.abstractAbgenix and Amgen (formerly Immunex) are developing ABX-EGF, a human monoclonal antibody against the epidermal growth factor receptor, for potential use in the treatment of cancer. ABX-EGF is undergoing phase II trials in patients with renal, colorectal, prostate and non-small-cell lung cancers. By July 2002, phase III trials for these indications were planned to start in 2003.


This item appears in the following Collection(s)

Show simple item record